Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Stem cell therapy stories

Oct 30, 2026

First patient receives Sumitomo Pharma stem cell transplant for Parkinson's disease

A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.

Oct 30, 2026·3 sources
00
Oct 29, 2026

Stem cell transplants show 60% progression-free survival at 10 years for severe systemic sclerosis

An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.

Oct 29, 2026·3 sources
00

Study finds air pollution accelerates stem cell aging in people with diabetes

Research led by Professor Sung-Ho Kook at Jeonbuk National University found that PM2.5 exposure activates inflammation in lungs and bone marrow, accelerating cellular aging and impairing stem cell function particularly in diabetic subjects. The study showed reduced bone mineral density and faster aging in diabetic mice exposed to fine particulate matter.

Oct 29, 2026·4 sources
00
Aug 6, 2026

Medical community scrutinizes stem cell and orthobiologic treatments amid variable outcomes and thin evidence

Healthcare professionals are raising concerns about the rapid growth of stem cell injections and orthobiologic treatments like platelet-rich plasma for conditions such as knee osteoarthritis, citing inconsistent results and insufficient scientific evidence despite increasing patient demand.

Aug 6, 2026·4 sources
00
Jul 21, 2026

Japanese Phase 1 Trial Supports Medium-Term Safety of iPSC-Derived Neural Stem/Progenitor Cell Therapy for Spinal Cord Injury

A Phase 1 clinical trial in Japan reported no tumor formation or graft-related adverse events after transplanting iPSC-derived neural stem/progenitor cells into four patients with subacute complete cervical spinal cord injuries during two to four years of follow-up. The small, uncontrolled study was designed primarily to assess safety and was not able to establish treatment efficacy.

Jul 21, 2026·3 sources
00

Top claims

  • ▪Parkinson's cell therapy developer Aspen Neuroscience raised $140.6 million in its initial public offering, selling 9.4 million shares at $15 each
  • ▪Sumitomo Pharma plans to perform induced pluripotent stem cell transplants on 20 to 30 Parkinson's disease patients by March 2029 while conducting a clinical trial in the United States.
  • ▪Aspen Neuroscience's experimental therapy sasineprocel modifies skin cells harvested from individual Parkinson's patients into autologous precursor cells to replenish dopamine-producing neurons.

People involved

Shashank Joshi

Subtopics

Regenerative medicine3Clinical trials2Drug Policy, Pricing & Approval2Aging (Biology)1Air pollution1Autoimmune disease1Autoimmune disease treatments1Biomedical research1Biotech innovation1Clinical evaluation1Clinical guidelines1Clinical Trial Design & Evaluation1Diabetes management1Drug Approval and Clinical Trials1Environmental and Occupational Health1Hematology1Inflammation reduction & immune effects1Longevity & aging1Media regulation1Medical research1Neurodegenerative disease1Observational research1Rare diseases1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories